| Name | Title | Contact Details |
|---|
Cook Pharmica is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Bloomington, IN. To find more information about Cook Pharmica, please visit www.cookpharmica.com
Anulex Technologies is a Hopkins, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Interactive Health, the country’s leading provider of health management solutions, creates innovative wellness programs designed to increase overall company health and actively engage employees to make lasting behavior changes. For every company’s perspective on health management, early stage or mature, Interactive Health has a highly flexible program to meet its needs. By offering health evaluations that detect risk proactively, Interactive Health has the capability to immediately intervene and engage at-risk participants with a personalized course of action. Using ActiveEngine(TM), a proprietary algorithmic-based clinical intelligence engine, a unique achievable goal is assigned to each participant based on individual results and health improvements are measured. Interactive Health has a 20+ year track record of creating the Healthiest Companies in America.
Century Park Associates is a Chattanooga, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TherOx, Inc. (TherOx) is a private, venture-financed medical device company based in Irvine, California, dedicated to elevating the standard of care for treatment of heart attack patients. A heart attack is caused when an artery in the heart becomes blocked. Current treatment of heart attack is to reestablish blood flow in the blocked artery as quickly as possible. Typically, this is done with a combination of medication and a percutaneous coronary intervention (PCI) which may include the placement of a (intracoronary) stent. PCI successfully restores blood flow, but damage to the patient’s heart remains. Blood flow in the microvasculature downstream from the blockage is compromised, and critical heart muscle tissue is damaged – or infarcted – due to oxygen deprivation brought on by the heart attack. The intent of SuperSaturated Oxygen (SSO2) Therapy from TherOx is to salvage damaged heart tissue by placing a high concentration of oxygen (~760 – 1,000 mmHg, or 5 – 7 times normal levels) into the patient’s blood plasma and delivering it directly to the area impacted by the heart attack. SSO2 Therapy serves as a complement to PCI and stenting. Immediately following the interventional procedure, proprietary technology from TherOx mixes a pre-specified concentration of “SuperOxygenated” saline solution with the patient’s blood to produce SuperOxygenated blood. The SuperOxygenated blood is then delivered through a catheter to the oxygen deficient tissue. Company research has confirmed in clinical studies that SuperSaturated Oxygen Therapy has the potential to reverse ischemia and may resuscitate tissue that may otherwise die. SSO2 Therapy circulates the patient`s own blood via the existing arterial access site used for the stenting procedure. Thus, no new access site is required. The TherOx DownStream System and DownStream Cartridge bear the CE Mark but are not available for commercial distribution in the EU at this time.